Introduction
============

Oral squamous cell carcinoma (OSCC) is the sixth most common malignant tumor type worldwide, accounting for nearly 529,500 new cases and 292,300 deaths per year ([@b1-etm-0-0-7998]). Despite the advances in surgery, radiation therapy and chemotherapy, the long-term survival rate for OSCC has only improved by a small amount in the last three decades ([@b1-etm-0-0-7998]--[@b3-etm-0-0-7998]). Most OSCC patients are diagnosed at an advanced clinical stage, which is usually associated with poor prognosis ([@b4-etm-0-0-7998],[@b5-etm-0-0-7998]). Therefore, it is essential and urgent to diagnose OSCC at an earlier stage and explore potential therapeutic targets.

Increasing evidence has demonstrated that multiple genetic and epigenetic alterations are responsible for the genesis and progression of OSCC. A study has indicated that α-protein kinase 1 (ALPK1) is associated with lymph node metastases and tumor development in OSCC, probably via regulation of cell growth, migration and invasion ([@b6-etm-0-0-7998]). Similarly, tumor-associated calcium signal transducer 2 (TROP2) was also determined to be involved in cell differentiation, TNM stage and vascular invasion ([@b7-etm-0-0-7998]). Although certain studies have reported on several genetic or epigenetic alterations contributing to OSCC, the molecular mechanisms of OSCC requires further elucidation.

Recent additions to the Cancer Genome Atlas (TCGA) provide abundant expression profiles from patient samples, as well as the associated clinicopathological data for \>30 human cancer types ([@b8-etm-0-0-7998],[@b9-etm-0-0-7998]). With the bioinformatics methods developed, integrated data analyses may be performed to further assist oncology research in several ways, including primary identification of dysregulated genes. In the present study, 2,013 differentially expressed (DE) mRNAs were identified from TCGA data. To further clarify the potential association between dysregulated mRNAs and clinical outcomes, 180 DEmRNAs were filtered according to the clinical features of patients \[pathological N stage, T stage and pathological stage based on TNM staging system ([@b10-etm-0-0-7998])\], 26 of which were aberrantly expressed regarding all 3 different types of subgroup. Finally, 6 survival-associated genes \[DDB1 and CUL4 associated factor 4 like 2 (DCAF4L2), opiorphin prepropeptide (OPRPN), R3H domain containing like (R3HDML), transmembrane phosphatase with tensin homology (TPTE), actin like 8 (ACTL8) and protocadherin α 11 (PCDHA11)\] were identified from Kaplan-Meier survival curves with the log-rank test.

Materials and methods
=====================

### Patients and samples

Original The Cancer Genome Atlas (TCGA) sequencing data and corresponding clinical information were obtained from TCGA database (<https://portal.gdc.cancer.gov/>) in October 2018. After excluding the patients without specific clinicopathological features (Tx and Nx), a total of 307 patients and 30 normal controls provided by TCGA dataset for OSCC were included. The clinical and pathological characteristics of the OSCC patients included are presented in [Table I](#tI-etm-0-0-7998){ref-type="table"}. No paired test was used to check whether the groups were age/sex-matched. Ethical approval was not required for the present study, since the data were downloaded from a publically available and open-ended TCGA database and did not involve primary data from human subjects.

### Analysis of differential expression profiles

DEmRNAs between OSCC and normal tissues were identified using the edgeR package from Bioconductor analysis tools (<https://bioconductor.org/packages/release/bioc/html/edgeR.html>). For multiple testing corrections, a false discovery rate (FDR) was applied to all P-values. The cut-off criteria were set as absolute \|log~2~fold change (FC)≥2\| and FDR\<0.01.

### Associations between DEmRNA and clinical features

The selected DEmRNAs were analyzed to determine whether they were differentially expressed in different clinical feature categories, including pathological T stage (T3 + T4 vs. T1 + T2), pathological N stage (N2 + N3 vs. N0 + N1) and pathological stage (stage III + IV vs. stage I + II). DEmRNAs with \|log~2~FC\|≥1.5 and FDR\<0.05 were regarded as being significantly linked to the relevant clinical feature.

### Functional enrichment analysis

Functional enrichment analysis was performed for clinical feature-associated DEmRNAs (CFmRNAs) to reveal the functional role of these mRNAs in the oncogenesis of OSCC. The Database for Annotation Visualization and Integrated Discovery (DAVID) online tool (<https://david.ncifcrf.gov/>) was employed to perform such functional and pathway enrichment analyses. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were applied to determine the potential biological functions and pathways of the CFmRNAs (P\<0.05).

### Protein-protein interaction (PPI) network construction

The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) online database (<http://string-db.org>) is a search tool for identifying and describing PPIs via review of recorded interactions. This tool was used to analyze the PPIs of CFmRNAs. In addition, Cytoscape software (version 3.6.1; <http://www.cytoscape.org/>) was then utilized to visualize the PPI network of the CFmRNAs.

### Survival analysis

For each CFmRNA, the OSCC patients were classified into either a high expression group or a low expression group. The median expression value of the respective CFmRNA was used as the cut-off value. The differences in survival time between the groups were then evaluated by Kaplan-Meier survival curves and the log-rank test to identify CFmRNAs that were significantly associated with survival in OSCC. The threshold for statistical significance was set as P\<0.05.

Results
=======

### DEmRNAs in OSCC

Based on the screening conditions as \|log~2~FC\|≥2 and FDR\<0.01, a total of 675 (33.53%) upregulated and 1,338 (66.47%) downregulated genes were identified in OSCC ([Table SI](#SD1-etm-0-0-7998){ref-type="supplementary-material"}). A volcano plot was drawn to visualize the distribution of DEmRNAs between OSCC and normal controls ([Fig. 1](#f1-etm-0-0-7998){ref-type="fig"}).

### DEmRNAs in association with clinical parameters

In order to further understand the association between dysregulated mRNAs and patient outcomes, associations between DEmRNAs and clinical characteristics, including pathologic T, pathologic N and pathologic stage, were analyzed. The expression levels of 180 DEmRNAs were significantly different in the clinical feature comparisons (\|log~2~FC\|≥1.5 and FDR\<0.05). Among them, 95 mRNAs were differentially expressed between the pathologic T subgroups, 79 mRNAs were differentially expressed between the pathologic N subgroups and 120 mRNAs were differentially expressed between the pathologic stage subgroups ([Table SII](#SD1-etm-0-0-7998){ref-type="supplementary-material"}). The corresponding volcano plots are provided in [Fig. 2](#f2-etm-0-0-7998){ref-type="fig"}. Finally, 26 mRNAs were screened out for all types of subgroups ([Fig. 3](#f3-etm-0-0-7998){ref-type="fig"}).

### GO and pathway enrichment analysis

GO and pathway enrichment analyses of the identified CFmRNAs were performed using DAVID ([Fig. 4](#f4-etm-0-0-7998){ref-type="fig"}). A total of 17 GO terms significantly enriched by the CFmRNAs were identified ([Table II](#tII-etm-0-0-7998){ref-type="table"}). In the GO category Biological Process, the dysregulated genes were particularly enriched in terms including retina homeostasis, saliva secretion, gonadal mesoderm development, epithelial cell differentiation and negative regulation of serine-type endopeptidase activity. In the Cellular Component category, the genes were enriched in the terms extracellular region, extracellular space, intermediate filament and extracellular exosome. In the GO category Molecular Function, the CFmRNAs were mainly enriched in calcium ion binding, vitamin D binding and serine-type endopeptidase inhibitor activity.

The results of the KEGG pathway enrichment analysis are displayed in [Fig. 4](#f4-etm-0-0-7998){ref-type="fig"}. The most significant pathways associated with CFmRNAs were salivary secretion, drug metabolism-cytochrome P450, metabolism of xenobiotics by cytochrome P450 and chemical carcinogenesis.

### Key candidate genes identified from the CFmRNA PPI network

The STRING online database was used to further investigate the potential links between abnormally expressed genes. A PPI network was visualized by Cytoscape and is provided in [Fig. 5](#f5-etm-0-0-7998){ref-type="fig"}. A total of 4 central node genes (\>7 connections/interactions) were identified, including albumin (ALB), statherin (STATH), neurotensin (NTS) and mucin 7, secreted (MUC7).

### CFmRNAs associated with survival

CFmRNAs associated with survival were detected by Kaplan-Meier survival curves and log-rank tests. A total of 6 CFmRNAs were identified to have a significant influence on the overall survival rate (P\<0.05). Of these, 4 (DCAF4L2, OPRPN, R3HDML and TPTE) were associated with a favorable prognosis regarding overall survival ([Fig. 6](#f6-etm-0-0-7998){ref-type="fig"}). Patients with higher expression of these mRNAs had a tendency for longer survival, compared with patients with lower expression (P\<0.05). ACTL8 and PCDHA11 were associated with an elevated risk, since their higher expression was associated with shorter overall survival of OSCC patients.

Discussion
==========

In spite of diagnostic and therapeutic advances in the last decades, OSCC remains a huge threat to human health. With the rapidly developed technology for gene analysis, in-depth exploration of the molecular characteristics and identification of potential valuable prognostic biomarkers for OSCC may be performed ([@b11-etm-0-0-7998]). The multi-step progression of carcinogenesis in the oral cavity, including gene amplification or dysregulation, has an important role in OSCC ([@b7-etm-0-0-7998]). In the present study, 675 upregulated and 1,338 downregulated mRNAs between OSCC and normal samples were initially identified. Of these DEmRNAs, 180 were screened out according to their association with clinical features. Furthermore, 6 survival-associated genes were identified (DCAF4L2, OPRPN, R3HDML, TPTE, ACTL8 and PCDHA11).

In the GO and KEGG analyses, 17 enriched terms and 4 signaling pathways were identified. They were involved in several relevant processes, particularly in saliva secretion and metabolism by cytochrome P450. The epithelium of the oral cavity is continuously immersed in saliva and its associated compositions, and thus, changes in the saliva composition may particularly affect the state of oral tissues ([@b12-etm-0-0-7998]).

The PPI network of the CFmRNAs comprised four hub genes (ALB, STATH, NTS and MUC7). STATH is derived from a secretory calcium-binding phosphoprotein gene cluster and encodes the protein statherin. It was reported to be responsible for preventing calcium phosphate precipitation in saliva, leading to persistent high calcium and phosphate levels ([@b13-etm-0-0-7998],[@b14-etm-0-0-7998]). The levels of statherin in saliva are significantly reduced in cancerous and pre-cancerous lesions compared with those in healthy controls ([@b15-etm-0-0-7998]). Decreased expression of STATH means less free calcium, perhaps resulting in initiation of sustained proliferation and reduction of desmosomes, as well as alterations in calcium-associated cellular functions. Dysfunction of this gene may be a possible mechanism of carcinogenesis in OSCC.

Overexpression of NTS and its affinity receptor NTSR1 are frequently detected in cancerous tissues ([@b16-etm-0-0-7998],[@b17-etm-0-0-7998]). Numerous studies have reported that NTS is associated with tumor progression in several solid tumor types, including breast cancer, lung cancer and hepatocellular carcinoma (HCC) ([@b18-etm-0-0-7998]--[@b20-etm-0-0-7998]). Recent studies on HCC demonstrated that NTS/NTSR1 co-expression promotes tumor invasion and epithelial-mesenchymal transition via Wnt/β-catenin signaling and the NTS/interleukin-8 pathway ([@b21-etm-0-0-7998],[@b22-etm-0-0-7998]). However, further evidence is necessary to prove the role of NTS in the progression of OSCC.

Mucins are multifunctional glycoproteins, which may be divided into membrane-bound and secreted protein ([@b23-etm-0-0-7998]). MUC7 is one of these secreted mucins identified in the PPI network of the screened CFmRNAs. Higher expression of MUC7 was previously reported to be associated with poor overall survival in clear-cell renal cell carcinoma ([@b24-etm-0-0-7998]). In the oral cavity, MUC7 acts as an innate immunity component, interacting with several oral microorganisms ([@b25-etm-0-0-7998]). MUC7 is typically distributed in normal salivary glands, while MUC7 is rarely expressed in malignant transformations into mucoepidermoid carcinoma ([@b23-etm-0-0-7998],[@b26-etm-0-0-7998]). The secreted proteins MUC5B and MUC6 were identified to be dysregulated among the pathological T, N and stage subgroups in the present study. A previous study suggested that MUC5B may be associated with poor prognosis regarding survival in lung cancer ([@b27-etm-0-0-7998]). The also associated MUC1 belongs to the transmembrane mucins. It has been indicated that MUC1 is a reliable biomarker to predict the metastatic/invasive potential of OSCC ([@b28-etm-0-0-7998],[@b29-etm-0-0-7998]). However, further research is required to elucidate the detailed function of MUC7 in OSCC.

From the 180 CFmRNAs, six mRNAs were identified that were able to predict the survival probability. DCAF4L2, OPRPN, R3HDML and TPTE were regarded as protective, as their expression was associated with consistently increased survival rates. DCAF4L2 is a member of the WD-repeat proteins, which commonly mediates protein-protein interlay ([@b30-etm-0-0-7998]), and its expression is a potential cause of cleft lip with or without cleft palate ([@b31-etm-0-0-7998]). In the present study, DCAF4L2 expression was elevated in tumor tissues, but was also associated with an increased survival rate. This may due to increases in the expression of DCAF4L2, which promotes polyubiquitination of protein phosphatase, Mg^2+/^Mn^2+^-dependent 1B (PPM1B) and then decreases in the totality of PPM1B ([@b32-etm-0-0-7998]). Reduced PPM1B in U2OS cells combined with anti-cancer drugs suppresses cellular proliferation of these cells and lowers the threshold of cell death ([@b33-etm-0-0-7998]). In colorectal cancer, upregulated DCAF4L2 induces neoplastic cell invasion and metastasis ([@b32-etm-0-0-7998]). OPRPN (also known as PROL1) localizes on chromosome 4q13.3, encoding basic proline-rich lacrimal protein ([@b34-etm-0-0-7998],[@b35-etm-0-0-7998]). In addition, dysregulated OPRPN was reported to be associated with invasion in breast cancer ([@b36-etm-0-0-7998]).

TPTE and ACTL8 belong to the cancer-testis antigens (CTAs). In the present study, elevated TPTE indicated longer overall survival, while higher expression of ACTL8 predicted a worse prognosis. Similarly, prolonged survival of TPTE-seropositive lung cancer patients was reported in a previous study ([@b37-etm-0-0-7998]). CTAs consist of tumor-associated antigens that are widely distributed in tumors, and are prospective targets for cancer immunotherapy ([@b38-etm-0-0-7998]). Previous studies have already proved that CT genes are more frequently expressed in invasive head and neck squamous cell carcinoma (HNSCC) and are associated with an unfavorable phenotype ([@b39-etm-0-0-7998],[@b40-etm-0-0-7998]). Furthermore, the proliferation and migration of HNSCC PCI-12 cells were significantly inhibited by knockdown of ACTL8 ([@b41-etm-0-0-7998]). On the contrary, co-expression of ACTL8, CCCTC-binding factor like, Opa interacting protein 5 and X antigen family member 3 may be associated with increased overall survival in glioblastoma patients ([@b42-etm-0-0-7998]). Taken together, these results suggest the prospect of CT genes as prognostic biomarkers that may be useful in the development of vaccine treatments based on CTAs ([@b43-etm-0-0-7998]).

At present, little is known regarding the role of dysregulated R3HDML and PCDHA11 in various diseases, including OSCC, and further research is required to investigate their potential molecular mechanisms. Of note, the present study has certain limitations. For instance, it lacks corresponding experiments to validate the *in silico* results; therefore, further experiments, including quantitative PCR analysis, are required to confirm the association of the genes identified with OSCC in future studies. Furthermore, a paired-test was not performed to assess whether the groups were age/sex-matched in the current study, which needs to be taken in to account in further studies.

In conclusion, six differently expressed genes linked to oncogenesis and development were identified to be associated different clinical features in the present study. These genes (DCAF4L2, OPRPN, R3HDML, TPTE, ACTL8 and PCDHA11) may serve as potential prognostic markers for OSCC. Although further experimental verification is imperative, these results may provide a basis for in-depth study regarding the diagnosis, therapy and prognosis of OSCC.
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###### 

Clinicopathological characteristics of 307 patients with oral squamous cell carcinoma.

  Subtype                              N (%)
  ------------------------------------ ------------
  Age (years)                          
    \<60                               132 (43)
    ≥60                                175 (57)
  Sex                                  
    Male                               207 (67.4)
    Female                             100 (32.6)
  Ethnicity                            
    White                              266 (86.6)
    Black or African American          21 (6.8)
    Asian                              9 (2.9)
    American Indian or Alaska native   1 (0.3)
    Not available                      10 (3.3)
  Pathologic stage                     
    I                                  19 (6.2)
    II                                 51 (16.6)
    III                                54 (17.6)
    IV                                 160 (52.1)
    Not available                      23 (7.5)
  Pathologic T-stage                   
    T1                                 29 (9.4)
    T2                                 94 (30.6)
    T3                                 57 (18.6)
    T4                                 109 (35.5)
    TX                                 9 (2.9)
    Not available                      9 (2.9)
  Pathologic N-stage                   
    N0                                 115 (37.5)
    N1                                 46 (15)
    N2                                 100 (32.6)
    N3                                 2 (0.7)
    NX                                 34 (11.1)
    Not available                      10 (3.3)
  Pathologic M-stage                   
    M0                                 116 (37.8)
    MX                                 33 (10.7)
    Not available                      158 (51.5)
  Survival status                      
    Alive                              166 (54.1)
    Dead                               141 (45.9)

###### 

Gene ontology analysis of differentially expressed genes in association with clinical parameters in oral squamous cell carcinoma.

  Category/term                                                                                  N (%)       P-value       Genes
  ---------------------------------------------------------------------------------------------- ----------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GOTERM_CC_DIRECT                                                                                                         
    GO:0005576\~extracellular region                                                             34 (19.1)   2.12×10^−6^   GC, DCD, C7, BPIFB6, STATH, GAST, HTN3, TAC3, SPINK7, SPINK9, TTR, ALB, GP2, PIP, LTF, FGF3, PRB2, CRISP3, BPIFA2, SCUBE3, BPIFA1, OPRPN, R3HDML, DHRS7C, MUC6, IL22, PLG, NTS, C4ORF26, CST5, WIF1, SCGB3A2, SMR3A, DMBT1
    GO:0005615\~extracellular space                                                              29 (16.3)   1.12×10^−5^   GC, DCD, BPIFB2, PRH2, MSMB, C6ORF58, SPINK1, GAST, OSTN, SCGB1A1, TAC3, ZG16B, TTR, ALB, PIP, LTF, TFF1, FGFBP2, CRISP3, BPIFA1, OPRPN, IL22, PLG, CST5, SCGB3A1, EPYC, MUC5B, DMBT1, SMR3B
    GO:0005882\~intermediate filament                                                            6 (3.4)     0.002961      KRT36, KRT27, KRT40, KRTAP17-1, KRTAP19-5, KRTAP13-2
    GO:0070062\~extracellular exosome                                                            38 (21.3)   0.004723      GC, DCD, C7, BPIFB2, PKHD1, C6ORF58, ALDOB, AQP5, SPINK1, CRNN, CALB1, SCGB1A1, TAC3, ZG16B, TTR, KRT27, ALB, UPK1A, GP2, PIP, LTF, TGM3, KRT84, CRISP3, GSTA2, BPIFA2, VIL1, ARMC3, MUC7, PLG, LRRC26, KRT36, PYGM, CST5, SCGB3A1, MUC5B, DMBT1, SMR3B
  GOTERM_BP_DIRECT                                                                                                         
    GO:0001895\~retina homeostasis                                                               5 (2.8)     2.38×10^−4^   ZG16B, ALB, PIP, LTF, OPRPN
    GO:0046541\~saliva secretion                                                                 3 (1.7)     5.68×10^−4^   CHRM1, STATH, AQP5
    GO:0007506\~gonadal mesoderm development                                                     3 (1.7)     0.001567      TSPY2, TSPY1, TSPY10
    GO:0030855\~epithelial cell differentiation                                                  5 (2.8)     0.002003      GSTA2, UPK1A, VIL1, DMBT1, ACTL8
    GO:1900004\~negative regulation of serine-type endopeptidase activity                        3 (1.7)     0.00362       SPINK9, SPINK1, SPINK7
    GO:0007548\~sex differentiation                                                              3 (1.7)     0.01426       TSPY1, DMRT1, TSPY10
    GO:1900229\~negative regulation of single-species biofilm formation in or on host organism   2 (1.1)     0.015188      BPIFA1, LTF
    GO:0060349\~bone morphogenesis                                                               3 (1.7)     0.017868      LTF, IFITM5, PAX1
    GO:0042742\~defense response to bacterium                                                    5 (2.8)     0.02499       DCD, BPIFA2, STATH, HTN3, MUC5B
    GO:0043367\~CD4-positive, alpha-beta T cell differentiation                                  2 (1.1)     0.037541      PAX1, NKX2-3
  GOTERM_MF_DIRECT                                                                                                         
    GO:0005509\~calcium ion binding                                                              12 (6.7)    0.033232      MYL7, SCUBE3, ANXA10, MYL3, CAPSL, RPTN, VIL1, TGM3, PCDHA11, CRNN, CALB1, NECAB2
    GO:0005499\~vitamin D binding                                                                2 (1.1)     0.040216      GC, CALB1
    GO:0004867\~serine-type endopeptidase inhibitor activity                                     4 (2.2)     0.045216      SPINK9, SPINK1, TFPI2, SPINK7

GO, Gene Ontology.
